Understanding kidney injury in preterm infants caused by gentamicin
Cellular and Molecular Response to Gentamicin-Induced Injury in Underdeveloped Kidneys
This study is looking at how the antibiotic gentamicin can harm the kidneys of premature babies, using a special mouse model to learn more about the injury and inflammation it causes, with the hope of finding better ways to protect and treat these little ones.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11012261 on NIH RePORTER |
What this research studies
This research investigates how gentamicin, a medication often given to preterm infants, causes kidney injury and contributes to chronic kidney disease. By using a novel mouse model that mimics the low nephron number found in premature kidneys, the study aims to uncover the cellular and molecular responses to this injury. The research focuses on understanding the inflammation and cell death processes that occur in the kidneys of these mice, which could lead to better prevention and treatment strategies for acute kidney injury in preterm infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants who are at risk of acute kidney injury due to low nephron endowment.
Not a fit: Patients who are not preterm or do not have a history of acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for preventing kidney injury in preterm infants, potentially reducing their risk of chronic kidney disease.
How similar studies have performed: Other research has shown promising results in understanding kidney injury mechanisms in similar contexts, but this specific approach using a novel mouse model is relatively new.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Good, Pamela Isabel — Columbia University Health Sciences
- Study coordinator: Good, Pamela Isabel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.